Statement: More patients in the primary trial suffer from dysfunctions with ventricular contractions than ventricular relaxations.
Primary_evidence: Adverse Events 1:   Total: 21/2125 (0.99%)   Febrile neutropenia 0/2125 (0.00%)   Hemoglobin 0/2125 (0.00%)   Cardiac General-Other 0/2125 (0.00%)   Cardiac-ischemia/infarction 1/2125 (0.05%)   Conduction abnorm/AV block - Sick sinus syndrome 0/2125 (0.00%)   Left ventricular diastolic dysfunction 0/2125 (0.00%)   Left ventricular systolic dysfunction 0/2125 (0.00%)   Pain - Cardiac/heart 0/2125 (0.00%) Adverse Events 2:   Total: 190/2186 (8.69%)   Febrile neutropenia 3/2186 (0.14%)   Hemoglobin 3/2186 (0.14%)   Cardiac General-Other 2/2186 (0.09%)   Cardiac-ischemia/infarction 1/2186 (0.05%)   Conduction abnorm/AV block - Sick sinus syndrome 1/2186 (0.05%)   Left ventricular diastolic dysfunction 3/2186 (0.14%)   Left ventricular systolic dysfunction 1/2186 (0.05%)   Pain - Cardiac/heart 3/2186 (0.14%)